In the world of pharmaceutical drugs, when a patent runs out on a drug—in theory—it is supposed to become a generic, meaning it contains the same formula and dosing as the name brand drug but is much cheaper. Patents are generally good for 20 years after the invention of the drug—not after it hits the market.
In 2009, the patent on Suboxone, the popular drug for treating opioid dependency, expired.
This put Suboxone’s manufacturer, Reckitt Benckiser pharmaceutical company, at risk of losing hundreds of millions of dollars, or 85 percent of its grip on the market, which is booming due to the out-of-control opioid epidemic, here in the U.S. and abroad.
So, the British multi-national decided to tweak Suboxone’s formula, then apply for a new patent. This tweaking, or “product hopping,” is used by pharmaceutical companies to obstruct generic competitors and preserve their monopoly.
Not so fast, said 35 U.S. states and the District of Columbia when they filed a huge anti-trust lawsuit last week against Reckitt Benckiser. According the Daily Beast, they are accusing the pill pushers of engaging in “deceptive and unconscionable” practices.
The product switch in question was from the orange Suboxone tablet to a new, dissolvable filmstrip, which is “…such a thin strip they’ll put it in the Holy Bible, let it melt and eat a page right out of the good book,” said a jailer at a Kentucky prison.
The 35 plaintiffs claim Reckitt Benckiser engaged in “feared-based messaging” and “sham science” to illegally subvert the market for the orange tablets while pushing their “new” product.
According to a criminal probe that began in 2013, Reckitt Benckiser allegedly compensated doctors and lobbied legislators to push the Suboxone filmstrips and even penalized their own employees for not meeting sales targets for the supposed “new drug.”
And, of course, they raised the price of the orange tablets, making them more expensive than the filmstrips, even though the pills are cheaper to make.
Then, in September 2012, claiming a “moral obligation,” Reckitt took the pills off the market and petitioned the FDA to block any generic tablets in the future, citing “pediatric exposure,”according to the New York Times. The FDA didn’t buy Reckitt’s rationale and approved the generic version of Suboxone in early 2013.
Consumer advocates agree that Reckitt Benckiser took product hopping to a new and nefarious level.
“Few, if any, companies have gone as far as to preemptively withdraw an off-patent drug from the market to make way for a newly patented successor…” said public advocacy group Public Citizen, in the Daily Beast.
Now, the question is: Will this anti-trust lawsuit succeed in penalizing Reckitt Benckiser for scheming to extend its monopoly while growing richer and richer by exploiting the opioid epidemic? Stay tuned.
For all of HIGH TIMES’ news coverage, click here.
Florida’s Largest Police Force Stops Detaining People Over Pot Smell
Beyond the Streets: Cannabis Isn’t the Only Counter Culture en Vogue
What’s in Your Stash? Sharon Letts, Producer, and Writer
Daniel Sloss: Sometimes They’re More Than Just Jokes
House Votes to Protect States With Legal Marijuana From Feds
Two Plead Guilty to Using United States Postal Service to Traffic Marijuana
Raid of Massive Illegal Cannabis Grow Site in California Took Four Days to Complete
What Was Said at Today’s Congressional Hearing on Federal Marijuana Law Reform
News4 days ago
Someone Planted 34 Cannabis Plants in the Vermont Statehouse Flower Beds
Entertainment5 days ago
Recreational Cannabis Comes to Northern Nights Music Festival
Culture4 days ago
What’s in Your Stash? Autumn Saylor, Stay-at-Home Mom, Treating PTSD With Cannabis
News2 days ago
Notorious Drug Kingpin ‘El Chapo’ Sentenced to Life in Prison
Activism4 days ago
Navigating Child Protective Services When You Use Cannabis
News4 days ago
Study Finds Legal Cannabis Reduces Illicit Grows in National Forests
Sponsored2 days ago
I Take CBD Oil. Will I Pass a Drug Test?
News2 days ago
West Hollywood Set To Get “First of Its Kind” Cannabis Café